BioRestorative Therapies to Showcase Innovations at 2025 Maxim Growth Summit
Melville, Wednesday, 15 October 2025.
BioRestorative Therapies, Inc. will participate in the 2025 Maxim Growth Summit to highlight its advancements in regenerative medicine, aiming to attract investors and solidify its biotech sector position.
BioRestorative Therapies at the Maxim Growth Summit
BioRestorative Therapies, Inc. (NASDAQ:BRTX), based in Melville, New York, is set to participate in the 2025 Maxim Growth Summit on October 22-23, 2025. This event, held at The Hard Rock Hotel in New York City, provides a significant platform for emerging growth companies to showcase their innovations and connect with potential investors. BioRestorative aims to leverage this opportunity to highlight its advancements in regenerative medicine and therapeutic solutions, reinforcing its position in the biotech sector amidst a rapidly evolving market landscape [1].
Key Participants and Agenda
Lance Alstodt, the CEO of BioRestorative, along with Francisco Silva, the Vice President of Research and Development, will participate in a pivotal panel discussion titled ‘Stem Cell Therapy – A Space That is Ready to have its Day.’ This panel, moderated by Jason McCarthy, Ph.D., Maxim Group’s Senior Managing Director and Head of Biotechnology Research, aims to explore the current and future potential of stem cell therapies, underlining the innovative strides made by BioRestorative in this field [1].
Advancements in Regenerative Medicine
BioRestorative has been at the forefront of developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The company has two core clinical development programs: the Disc/Spine Program (brtxDISC™) and the Metabolic Program (ThermoStem®). The Disc/Spine Program’s lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells, intended for non-surgical treatment of painful lumbosacral disc disorders [1].
Metabolic Program and Future Prospects
In addition to its Disc/Spine Program, BioRestorative is developing cell-based therapy candidates under its Metabolic Program. This initiative focuses on using brown adipose (fat) derived stem cells to generate brown adipose tissue, targeting obesity and metabolic disorders. Researchers suggest that higher levels of brown fat may reduce the risk of obesity and diabetes, positioning BioRestorative’s innovations as potentially transformative in these areas [1].